COVID-19: How Orbis International is managing operations

Article

Danny Haddad, MD, chief of program at Orbis International, shares an update on how the company's operations have shifted during the coronavirus pandemic, as well as the record-breaking impact on one of its telehealth platforms.
 


See more coronavirus coverage here

 

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
Related Content
A syringe and containers of liquid in front of the European Medicines Agency logo. Concept image for aflibercept Eylea EMA approval. Image credit: ©SoniaBonet – stock.adobe.com

Bayer submits EMA application for aflibercept 8mg third indication, retinal vein occlusion

Hattie Hayes
April 9th 2025
Article

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

An image of two older adults on a bench. Concept image for giant cell arteritis and vision loss from sudden ocular change in vasculitis. Image credit: ©C Coetzee/peopleimages.com – stock.adobe.com

European Commission expands upadacitinib (Rinvoq) indication to include giant cell arteritis

Hattie Hayes
April 8th 2025
Article

Patients with GCA, an autoimmune disease, are at risk for sudden vision loss which can be permanent

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A dermatologist examines a child's arm for evidence of atopic dermatitits. Concept image for link between AD and paediatric uveitis. Image credit: ©Kate – stock.adobe.com

Paediatric patients with early-onset atopic dermatitis show higher uveitis risk

Lynda Charters
April 8th 2025
Article

The study findings support the need to consider ophthalmologic monitoring in children with early-onset atopic dermatitis

A map of Europe with a digital overlay. Concept image for European EU commercialisation and CE mark. Image credit: ©garrykillian – stock.adobe.com

Canalicular gel Lacrifill (Nordic Pharma) receives CE Mark

Hattie Hayes
April 7th 2025
Article

Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment

© 2025 MJH Life Sciences

All rights reserved.